Segall Bryant & Hamill LLC Makes New Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Segall Bryant & Hamill LLC bought a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 40,633 shares of the biopharmaceutical company's stock, valued at approximately $808,000.

Other large investors have also recently made changes to their positions in the company. Sei Investments Co. raised its stake in shares of Catalyst Pharmaceuticals by 64.3% during the first quarter. Sei Investments Co. now owns 83,360 shares of the biopharmaceutical company's stock valued at $1,329,000 after acquiring an additional 32,621 shares in the last quarter. Vanguard Group Inc. increased its position in Catalyst Pharmaceuticals by 12.1% during the 1st quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company's stock valued at $127,212,000 after buying an additional 860,244 shares in the last quarter. American International Group Inc. boosted its holdings in Catalyst Pharmaceuticals by 10.0% in the first quarter. American International Group Inc. now owns 60,087 shares of the biopharmaceutical company's stock worth $958,000 after acquiring an additional 5,463 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its stake in shares of Catalyst Pharmaceuticals by 12.7% during the first quarter. CANADA LIFE ASSURANCE Co now owns 147,245 shares of the biopharmaceutical company's stock worth $2,346,000 after acquiring an additional 16,599 shares during the last quarter. Finally, Lazard Asset Management LLC raised its position in shares of Catalyst Pharmaceuticals by 36.6% in the 1st quarter. Lazard Asset Management LLC now owns 30,334 shares of the biopharmaceutical company's stock valued at $482,000 after purchasing an additional 8,133 shares during the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Stephens began coverage on shares of Catalyst Pharmaceuticals in a research note on Monday, November 18th. They set an "overweight" rating and a $35.00 price objective for the company. Citigroup raised their price objective on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a "buy" rating in a research note on Friday, August 9th. Truist Financial upped their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a "buy" rating in a research report on Monday, November 11th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, August 9th. Finally, HC Wainwright reissued a "buy" rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $31.14.

Catalyst Pharmaceuticals Stock Down 1.4 %

Shares of Catalyst Pharmaceuticals stock traded down $0.29 on Monday, reaching $21.19. The company's stock had a trading volume of 865,509 shares, compared to its average volume of 1,189,513. The company has a market capitalization of $2.53 billion, a P/E ratio of 17.96, a PEG ratio of 3.31 and a beta of 0.75. The stock has a 50-day moving average price of $21.13 and a 200-day moving average price of $18.59. Catalyst Pharmaceuticals, Inc. has a 52-week low of $13.00 and a 52-week high of $24.27.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.